297 related articles for article (PubMed ID: 35831538)
41. A Pooled Analysis of 3 Phase II Trials of Salvage Nivolumab/Ipilimumab After Nivolumab in Renal Cell Carcinoma.
McKay RR; Leucht K; Xie W; Jegede O; Braun DA; Atkins MB; Grimm MO; Choueiri TK
Oncologist; 2024 Apr; 29(4):324-331. PubMed ID: 37950901
[TBL] [Abstract][Full Text] [Related]
42. Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Yip SM; Wells C; Moreira R; Wong A; Srinivas S; Beuselinck B; Porta C; Sim HW; Ernst DS; Rini BI; Yuasa T; Basappa NS; Kanesvaran R; Wood LA; Canil C; Kapoor A; Fu SYF; Choueiri TK; Heng DYC
Cancer; 2018 Sep; 124(18):3677-3683. PubMed ID: 30307610
[TBL] [Abstract][Full Text] [Related]
43. PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma.
Buckley HL; Collinson FJ; Ainsworth G; Poad H; Flanagan L; Katona E; Howard HC; Murden G; Banks RE; Brown J; Velikova G; Waddell T; Fife K; Nathan PD; Larkin J; Powles T; Brown SR; Vasudev NS
BMC Cancer; 2019 Nov; 19(1):1102. PubMed ID: 31727024
[TBL] [Abstract][Full Text] [Related]
44. A multicenter retrospective study of nivolumab monotherapy in previously treated metastatic renal cell carcinoma patients: interim analysis of Japanese real-world data.
Hinata N; Yonese J; Masui S; Nakai Y; Shirotake S; Tatsugami K; Inamoto T; Nozawa M; Ueda K; Etsunaga T; Osawa T; Uemura M; Kimura G; Numakura K; Yamana K; Miyake H; Fukasawa S; Ochi K; Kaneko H; Uemura H
Int J Clin Oncol; 2020 Aug; 25(8):1533-1542. PubMed ID: 32519026
[TBL] [Abstract][Full Text] [Related]
45. Salvage nivolumab and ipilimumab after prior anti-PD-1/PD-L1 therapy in metastatic renal cell carcinoma: A meta-analysis.
Yang Y; Mori SV; Li M; Hinkley M; Parikh AB; Collier KA; Miah A; Yin M
Cancer Med; 2022 Apr; 11(7):1669-1677. PubMed ID: 35138046
[TBL] [Abstract][Full Text] [Related]
46. Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma.
Zarrabi KK; Handorf E; Miron B; Zibelman MR; Anari F; Ghatalia P; Plimack ER; Geynisman DM
Oncologist; 2023 Feb; 28(2):157-164. PubMed ID: 36200791
[TBL] [Abstract][Full Text] [Related]
47. Oncological Outcomes of Delayed Nephrectomy After Optimal Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma.
Pignot G; Thiery-Vuillemin A; Albigès L; Walz J; Lang H; Balssa L; Parier B; Geoffrois L; Bensalah K; Schlürmann F; Ladoire S; Bigot P; Borchiellini D; Cassuto O; Thibault C; Ingels A; Saldana V; Roubaud G; Bernhard JC; Gravis G; Barthélémy P
Eur Urol Oncol; 2022 Oct; 5(5):577-584. PubMed ID: 35853818
[TBL] [Abstract][Full Text] [Related]
48. The safety profile of nivolumab plus ipilimumab combination therapy in Japanese patients with renal cell carcinoma: results from post-marketing surveillance.
Uemura H; Shinohara N; Tomita Y; Nonomura N; Yamada T; Yoshida A; Komoto A
Jpn J Clin Oncol; 2023 Jul; 53(8):730-737. PubMed ID: 37151051
[TBL] [Abstract][Full Text] [Related]
49. Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors.
Gul A; Stewart TF; Mantia CM; Shah NJ; Gatof ES; Long Y; Allman KD; Ornstein MC; Hammers HJ; McDermott DF; Atkins MB; Hurwitz M; Rini BI
J Clin Oncol; 2020 Sep; 38(27):3088-3094. PubMed ID: 32491962
[TBL] [Abstract][Full Text] [Related]
50. Clinical Activity of Ipilimumab Plus Nivolumab in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma.
Gupta R; Ornstein MC; Li H; Allman KD; Wood LS; Gilligan T; Garcia JA; Merveldt DV; Hammers HJ; Rini BI
Clin Genitourin Cancer; 2020 Dec; 18(6):429-435. PubMed ID: 32800717
[TBL] [Abstract][Full Text] [Related]
51. First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
Wallis CJD; Klaassen Z; Bhindi B; Ye XY; Chandrasekar T; Farrell AM; Goldberg H; Boorjian SA; Leibovich B; Kulkarni GS; Shah PS; Bjarnason GA; Heng DYC; Satkunasivam R; Finelli A
Eur Urol; 2018 Sep; 74(3):309-321. PubMed ID: 29656851
[TBL] [Abstract][Full Text] [Related]
52. Immune-related adverse events are clinical biomarkers to predict favorable outcomes in advanced renal cell carcinoma treated with nivolumab plus ipilimumab.
Ueda K; Suekane S; Kurose H; Ito N; Ogasawara N; Hiroshige T; Chikui K; Ejima K; Uemura K; Nakiri M; Nishihara K; Igawa T
Jpn J Clin Oncol; 2022 May; 52(5):479-485. PubMed ID: 35141749
[TBL] [Abstract][Full Text] [Related]
53. Pembrolizumab plus axitinib and nivolumab plus ipilimumab as first-line treatments of advanced intermediate- or poor-risk renal-cell carcinoma: a number needed to treat analysis from the Brazilian private perspective.
Engel Ayer Botrel T; Datz Abadi M; Chabrol Haas L; da Veiga CRP; de Vasconcelos Ferreira D; Jardim DL
J Med Econ; 2021; 24(1):291-298. PubMed ID: 33538203
[TBL] [Abstract][Full Text] [Related]
54. Real-world clinical outcomes of patients with metastatic renal cell carcinoma receiving pembrolizumab + axitinib vs. ipilimumab + nivolumab.
Shah NJ; Sura SD; Shinde R; Shi J; Singhal P; Perini RF; Motzer RJ
Urol Oncol; 2023 Nov; 41(11):459.e1-459.e8. PubMed ID: 37722984
[TBL] [Abstract][Full Text] [Related]
55. Frontline immune checkpoint inhibitor-based combination therapy in metastatic renal cell carcinoma patients with poor performance status.
Carril-Ajuria L; Colomba E; Romero-Ferreiro C; Cerbone L; Ratta R; Barthelemy P; Vindry C; Fléchon A; Cherifi F; Boughalem E; Linassier C; Fornarini G; Rebuzzi SE; Gross-Goupil M; Saldana C; Martin-Soberón M; de Velasco G; Manneh R; Pernaut C; Sanchez de Torre A; Flippot R; Escudier B; Albiges L
Eur J Cancer; 2023 Feb; 180():21-29. PubMed ID: 36527973
[TBL] [Abstract][Full Text] [Related]
56. [DEFERRED NEPHRECTOMY IN A PATIENT WITH METASTATIC RENAL CELL CARCINOMA AFTER A NEAR-COMPLETE RESPONSE TO IMMUNOTHERAPY].
Purim O; Raz O; Eisner A; Baram N; Leonov Polak M; Rybo L
Harefuah; 2022 Dec; 161(12):763-768. PubMed ID: 36916116
[TBL] [Abstract][Full Text] [Related]
57. A Multicentre Retrospective Study of Nivolumab Plus Ipilimumab for Untreated Metastatic Renal Cell Carcinoma.
Kato R; Kojima T; Sazuka T; Yamamoto H; Fukuda S; Yamana K; Sugino Y; Hamamoto S; Nakaigawa N; Kabu K; Murakami H; Obara W
Anticancer Res; 2021 Dec; 41(12):6199-6209. PubMed ID: 34848474
[TBL] [Abstract][Full Text] [Related]
58. The lymphocyte-to-monocyte ratio as a significant inflammatory marker associated with survival of patients with metastatic renal cell carcinoma treated using nivolumab plus ipilimumab therapy.
Numakura K; Sekine Y; Osawa T; Naito S; Tokairin O; Muto Y; Sobu R; Kobayashi M; Sasagawa H; Yamamoto R; Nara T; Saito M; Narita S; Akashi H; Tsuchiya N; Shinohara N; Habuchi T
Int J Clin Oncol; 2024 Jul; 29(7):1019-1026. PubMed ID: 38797782
[TBL] [Abstract][Full Text] [Related]
59. First-line nivolumab plus ipilimumab with or without chemotherapy for Japanese patients with non-small cell lung cancer: LIGHT-NING study.
Imai H; Kijima T; Azuma K; Kishi K; Saito H; Yamaguchi T; Tanizaki J; Yoneshima Y; Fujita K; Watanabe S; Kitazono S; Fukuhara T; Hataji O; Toi Y; Mizutani H; Hamakawa Y; Maemondo M; Ohsugi T; Suzuki K; Horinouchi H; Ohe Y
Jpn J Clin Oncol; 2024 Apr; 54(4):452-462. PubMed ID: 38271158
[TBL] [Abstract][Full Text] [Related]
60. First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium.
Dudani S; Graham J; Wells JC; Bakouny Z; Pal SK; Dizman N; Donskov F; Porta C; de Velasco G; Hansen A; Iafolla M; Beuselinck B; Vaishampayan UN; Wood LA; Liow E; Yan F; Yuasa T; Bjarnason GA; Choueiri TK; Heng DYC
Eur Urol; 2019 Dec; 76(6):861-867. PubMed ID: 31445844
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
